These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 7904561)

  • 1. Radioiodinated somatostatin analogue RC-160: preparation, biological activity, in vivo application in rats and comparison with [123I-Tyr3]octreotide.
    Breeman WA; Hofland LJ; Bakker WH; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1993 Nov; 20(11):1089-94. PubMed ID: 7904561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
    Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.
    Bakker WH; Krenning EP; Breeman WA; Koper JW; Kooij PP; Reubi JC; Klijn JG; Visser TJ; Docter R; Lamberts SW
    J Nucl Med; 1990 Sep; 31(9):1501-9. PubMed ID: 1975618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.
    de Jong M; Breeman WA; Bernard BF; van Gameren A; de Bruin E; Bakker WH; van der Pluijm ME; Visser TJ; Mäcke HR; Krenning EP
    Eur J Nucl Med; 1999 Jul; 26(7):693-8. PubMed ID: 10398816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
    De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
    Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
    Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
    J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
    Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
    Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on radiolabeled somatostatin analogues in rats and in patients.
    Breeman WA; Bakker WH; De Jong M; Hofland LJ; Kwekkeboom DJ; Kooij PP; Visser TJ; Krenning EP
    Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours.
    Stolz B; Weckbecker G; Smith-Jones PM; Albert R; Raulf F; Bruns C
    Eur J Nucl Med; 1998 Jul; 25(7):668-74. PubMed ID: 9662587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.
    Hofland LJ; Breeman WA; Krenning EP; de Jong M; Waaijers M; van Koetsveld PM; Mäcke HR; Lamberts SW
    Proc Assoc Am Physicians; 1999; 111(1):63-9. PubMed ID: 9893158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
    Siehler S; Seuwen K; Hoyer D
    Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours.
    Smith-Jones PM; Stolz B; Albert R; Ruser G; Briner U; Mäcke HR; Bruns C
    Nucl Med Biol; 1998 Apr; 25(3):181-8. PubMed ID: 9620621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors.
    van Eyck CH; Bruining HA; Reubi JC; Bakker WH; Oei HY; Krenning EP; Lamberts SW
    World J Surg; 1993; 17(4):444-7. PubMed ID: 8395748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.